I-DXd
IDeate-Lung02: A Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Quizartinib
Hematology
FLT3-ITD measurable residual disease from the QuANTUM-First trial
Levis MJ, Erba HP, Montesinos P, et al.
Blood Adv. 2025:bloodadvances.2025016444. doi: 10.1182/bloodadvances.2025016444.
Dato-DXd
Tumor-agnostic
Population pharmacokinetic analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced solid tumors
Hong Y, Peigné S, Pan Υ, et al.
CPT Pharmacometrics Syst Pharmacol. 2025 Dec;14(12):2149-2160. doi: 10.1002/psp4.70118
Dato-DXd
Lung Cancer
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer
Jones DR, Opitz I, Harpole D, et al.
J Thorac Cardiovasc Surg. 2026 Jan;171(1):1-9. doi: 10.1016/j.jtcvs.2025.09.017.
T-DXd
Breast Cancer
Effectiveness of additional risk minimization measures related to interstitial lung disease/pneumonitis with trastuzumab deruxtecan treatment of breast cancer in European Countries: results and learnings from a post-authorization safety survey among physicians
Wientzek-Fleischmann A, Stellmacher U, Beyerlein E, Gohlke A, Ehlken B.
Pharmacoepidemiol Drug Saf. 2025;34(9):e70206. doi: 10.1002/pds.70206.
Valemetostat
Hematology
Population pharmacokinetics of valemetostat and exposure–response analyses of efficacy and safety in patients with relapsed/refractory peripheral T–cell lymphoma
Inoue H, Wang X, Garcia R, et al.
J Clin Pharmacol. 2025 Dec;65(12):1699-1711. doi: 10.1002/jcph.70100.
Quizartinib
Hematology
QuANTUM-First: Clinical validation of the LeukoStrat companion diagnostic for the selection of patients with acute myeloid leukemia harboring FMS-like tyrosine kinase 3-internal tandem duplications for treatment with quizartinib
Connolly Rohrbach JE, Chang KCN, Karnoub M, et el.
Arch Pathol Lab Med. 2025. doi: 10.5858/arpa.2024-0449-OA.
Pexidartinib
Hematology
A phase 3 study of the efficacy and safety of pexidartinib in east Asian patients with tenosynovial giant cell tumor
Xu H, Wu PK, Ye Z, et al.
Oncol Ther. 2025 Dec;13(4):1025-1039. doi: 10.1007/s40487-025-00365-z.
Edoxaban
Cardiovascular - AF
An efficient approach for detecting atrial fibrillation in ischemic stroke patients using a wearable device: a prospective multicenter substudy of the STABLED trial
Saito T, Nishiyama Y, Otsuka T, et al.
Front Neurol. 2025;16:1560495. doi: 10.3389/fneur.2025.1560495.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): Results from a single-arm, multicenter, phase 2 trial
Peng Z, Chen P, Lu J, et al.
EClinicalMedicine. 2025;87:103404. doi: 10.1016/j.eclinm.2025.103404.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below